GTBP · XBRL financial data
GT Biopharma financial statements, every fiscal year
The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (GTBP's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0 | — | — | — | — | — |
| Research and development | 485 | 9,591 | 8,811 | 6,466 | 5,798 | 3,472 |
| Selling, general and administrative | 6,279 | 47,924 | 12,446 | 7,110 | 8,566 | 8,950 |
| Total operating expenses | — | 57,515 | 21,257 | 13,576 | — | — |
| Operating income (loss) | 6,764 | (57,515) | (21,257) | (13,576) | (14,364) | (12,422) |
| Interest expense | (3,003) | 718 | 8 | 213 | — | 127 |
| Other income (expense) | — | 38 | — | 20 | — | 156 |
| Net income (loss) | (28,296) | (58,013) | (20,884) | (7,597) | (13,162) | (28,354) |
| Earnings per share, basic USD per share | — | (2.06) | (0.66) | (5.64) | (6.94) | (6.68) |
| Earnings per share, diluted USD per share | — | — | (19.66) | (5.64) | (6.94) | (6.68) |
| Weighted average shares, basic thousands of shares | — | 28,156 | 31,868 | 1,348 | 1,897 | 5,513 |
| Weighted average shares, diluted thousands of shares | 4,385 | — | 1,062 | 1,348 | 1,897 | 5,513 |
- † Share count changed about 1/27 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 14x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (GTBP's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 5,297 | 8,968 | 5,672 | 1,079 | 3,951 | 6,811 |
| Short-term investments | 0 | 23,011 | 10,836 | 12,893 | — | — |
| Prepaid and other current assets | 364 | 190 | 54 | 84 | 188 | 567 |
| Total current assets | 5,661 | 32,169 | 16,562 | 14,056 | 4,232 | 8,106 |
| Right-of-use asset | 0 | — | 165 | 53 | — | — |
| Total assets | 5,661 | 32,169 | 16,736 | 14,109 | 4,232 | 8,106 |
| Accounts payable | 2,243 | 8,189 | 3,140 | 4,328 | 3,853 | 748 |
| Accrued liabilities | 1,296 | 1,901 | 1,669 | 1,195 | 1,797 | 1,560 |
| Total current liabilities | 35,094 | 10,259 | 4,938 | 6,633 | 5,902 | 2,319 |
| Lease liability, non-current | — | — | 64 | — | — | — |
| Total liabilities | — | 10,259 | 5,002 | 6,633 | — | — |
| Accumulated deficit | (595,628) | (653,584) | (674,468) | (682,065) | (695,227) | (723,901) |
| Total stockholders' equity | (29,433) | 21,910 | 11,734 | 7,476 | (1,670) | 5,787 |
| Total liabilities and equity | 5,661 | 32,169 | 16,736 | 14,109 | 4,232 | 8,106 |
| Common shares outstanding (cover page) thousands of shares | 28,394 | 32,123 | 36,809 | 1,381 | 2,234 | 31,554 |
- † Share count changed about 1/27 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 14x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (GTBP's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (28,296) | (58,013) | (20,884) | (7,597) | (13,162) | (28,354) |
| Stock-based compensation | 269 | 33,900 | 7,700 | — | 230 | 432 |
| Net cash from operating activities | (7,262) | (15,606) | (15,217) | (8,852) | (12,904) | (12,914) |
| Net cash from investing activities | 0 | (23,040) | 12,145 | (2,009) | 12,893 | — |
| Proceeds from issuing common stock | — | 24,679 | — | 6,268 | — | — |
| Proceeds from issuing equity | — | — | — | 6,268 | 2,976 | — |
| Dividends paid | — | — | — | — | — | 229 |
| Net cash from financing activities | 12,531 | 42,317 | (224) | 6,268 | 2,976 | 15,775 |
| Net change in cash | 5,269 | 3,671 | (3,296) | (4,593) | 2,965 | 2,861 |
- † Share count changed about 1/27 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 14x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| GT Biopharma | 4,960 | not reported | (4,260)* | 45.1M | 1.2 quarters | 10-QJun 30, 2026 |
| Biovie | 8,977 | not reported | (4,122)* | 7.5M | 2.2 quarters | 10-KJun 30, 2026 |
| Talphera | 742 | not reported | (3,924)* | 51.9M | 4.4 quarters | 10-QJun 30, 2026 |
| TherapeuticsMD | 9,189 | not reported | not reported | 11.6M | — | 10-QJun 30, 2026 |
| Oncotelic Therapeutics | 186 | 250 | (92)* | 457.5M | 2.0 quarters | 10-QJun 30, 2026 |
| Processa Pharmaceuticals | 196 | not reported | (1,996)* | 2.8M | 0.1 quarters | 10-QJun 30, 2026 |
| Artelo Biosciences | 4,198 | not reported | (5,033)* | 4.6M | 0.8 quarters | 10-QJun 30, 2026 |
| Bioxytran | 177 | not reported | (350)* | 114.7M | 0.5 quarters | 10-QJun 30, 2026 |
| Raphael Pharmaceutical | 1 | not reported | 0* | 20.2M | — | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.